NCT00429364
Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome
See it on ClinicalTrials.gov ↗608 people
39.8%
60.2%
242 womenmiddle line = equal numbers366 men
- Phase
- PHASE3
- Paid for by
- Carelon Research
- Finished
- 2014-02
- Health conditions
- Marfan Syndrome
- Who could join
- Anyone
- Ages
- 6 Months – 25 Years
- Average age
- mean 11.2 years
- Age 65+
- 0%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 86.5% · Black / African American 7.6% · Other 3.3% · Asian 2.6%
Women left out
- Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 25 Years.”
- No pregnant women
Women who were pregnant could not join.
“Pregnant or planning to become pregnant within 36 months of study entry”
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Kidney dysfunction (i.e., creatinine greater than the upper limit of age-related normal values)”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Therapeutic (i.e., for arrhythmia, ventricular dysfunction, or valve regurgitation) rather than prophylactic use of angiotensin-converting enzyme (ACE) inhibitor, beta-blocker, or calcium channel blocker”
- No diabetes
Women with diabetes were turned away.
“Diabetes mellitus”
Study titles and rules are shown in their original English.